Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMT

Key Points

• Deutsche Bank acquired 710,942 shares of 4D Molecular Therapeutics in the second quarter, worth approximately $9.46 million and representing about 1.36% of the company. Institutional investors collectively own 99.27% of FDMT.
• 4D Molecular Therapeutics reported quarterly revenue of $3.78 million, above estimates, but its adjusted loss of $1.04 per share missed expectations. Insiders sold approximately $2.24 million worth of shares over the past quarter.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $29.62 versus the stock’s reported price of $15.83, although some analysts maintain sell or hold ratings.

Deutsche Bank AG acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 710,942 shares of the company's stock, valued at approximately $9,456,000. Deutsche Bank AG owned approximately 1.36% of 4D Molecular Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics during the 1st quarter worth about $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics in the 3rd quarter valued at about $41,000. AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics in the 1st quarter valued at about $46,000. Daiwa Securities Group Inc. increased its stake in 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company's stock worth $48,000 after purchasing an additional 6,186 shares during the period. Finally, Rangeley Capital LLC purchased a new stake in 4D Molecular Therapeutics during the second quarter worth about $48,000. Hedge funds and other institutional investors own 99.27% of the company's stock.

Insider Buying and Selling at 4D Molecular Therapeutics

In related news, insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the sale, the insider directly owned 871,737 shares in the company, valued at $8,760,956.85. This trade represents a 1.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company's stock, valued at approximately $103,404. This trade represents a 53.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 200,496 shares of company stock worth $2,240,244 over the last quarter. 7.90% of the stock is owned by company insiders.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $15.83 on Monday. The company has a market capitalization of $874.45 million, a price-to-earnings ratio of -6.02 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a 52-week low of $5.97 and a 52-week high of $16.93. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average price of $11.61 and a 200 day moving average price of $10.12.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The company had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. Research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on FDMT shares. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. The Goldman Sachs Group reaffirmed a "buy" rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. B. Riley Financial reiterated a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.62.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source